NovaBridge Biosciences (NBP) Notes Payables (2018 - 2023)

NovaBridge Biosciences (NBP) has 4 years of Notes Payables data on file, last reported at $4.2 million in Q4 2023.

• Quarterly Notes Payables rose 56.17% year-over-year to $4.2 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $4.2 million (up 56.17% YoY) and the FY2023 annual result came in at $4.2 million, down 99.85% from the prior year.
• Notes Payables climbed to $4.2 million in Q4 2023 per NBP's latest filing, from $4.1 million in the prior quarter.
• Across five years, Notes Payables topped out at $7.1 million in Q4 2019 and bottomed at $2.7 million in Q4 2022.
• The 3-year median for Notes Payables is $4.1 million (2023), against an average of $4.5 million.
• The widest annual swing landed in 2019, when Notes Payables sank 38.69%; it then surged 56.17% in 2023.
• Tracing NBP's Notes Payables over 3 years: stood at $7.1 million in 2019, then sank by 62.43% to $2.7 million in 2022, then surged by 56.17% to $4.2 million in 2023.
• Per Business Quant, the three latest NBP Notes Payables figures stand at $4.2 million (Q4 2023), $4.1 million (Q2 2023), and $2.7 million (Q4 2022).

Peer Comparison